Literature DB >> 9915269

Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.

J Gunnell1, J Y Yeun, T A Depner, G A Kaysen.   

Abstract

We defined erythropoietin (EPO) resistance by the ratio of the weekly EPO dose to hematocrit (Hct), yielding a continuously distributed variable (EPO/Hct). EPO resistance is usually attributed to iron or vitamin deficiency, hyperparathyroidism, aluminum toxicity, or inflammation. Activation of the acute-phase response, assessed by the level of the acute-phase C-reactive protein (CRP), correlates strongly with hypoalbuminemia and mortality in both hemodialysis (HD) and peritoneal dialysis (PD) patients. In this cross-sectional study of 92 HD and 36 PD patients, we examined the contribution of parathyroid hormone (PTH) levels, iron indices, aluminum levels, nutritional parameters (normalized protein catabolic rate [PCRn]), dialysis adequacy (Kt/V), and CRP to EPO/Hct. Albumin level serves as a measure of both nutrition and inflammation and was used as another independent variable. Serum albumin level (deltaR2 = 0.129; P < 0.001) and age (deltaR2 = 0.040; P = 0.040) were the best predictors of EPO/Hct in HD patients, and serum albumin (deltaR2 = 0.205; P = 0.002) and ferritin levels (deltaR2 = 0.132; P = 0.015) in PD patients. When albumin was excluded from the analysis, the best predictors of EPO/Hct were CRP (deltaR2 = 0.105; P = 0.003) and ferritin levels (deltaR2 = 0.051; P = 0.023) in HD patients and CRP level (deltaR2 = 0.141; P = 0.024) in PD patients. When both albumin and CRP were excluded from analysis in HD patients, low transferrin levels predicted high EPO/Hct (deltaR2 = 0.070; P = 0.011). EPO/Hct was independent of PTH and aluminum levels, PCRn, and Kt/V. High EPO/Hct occurred in the context of high ferritin and low transferrin levels, the pattern expected in the acute-phase response, not in iron deficiency. In well-dialyzed patients who were iron replete, the acute-phase response was the most important predictor of EPO resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915269     DOI: 10.1016/s0272-6386(99)70259-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  58 in total

1.  Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients.

Authors:  Alexander Kainz; Bernd Mayer; Reinhard Kramar; Rainer Oberbauer
Journal:  Nephrol Dial Transplant       Date:  2010-05-26       Impact factor: 5.992

2.  Reduced responsiveness to epoetin at re-exposure after prolonged epoetin-free period in anemic hemodialysis patients with end-stage renal disease.

Authors:  Slobodan Milutinović; Vladimir Trkulja
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

3.  Ethnic disparity in outcomes for pediatric peritoneal dialysis patients in the ESRD Clinical Performance Measures Project.

Authors:  Meredith A Atkinson; Alicia M Neu; Barbara A Fivush; Diane L Frankenfield
Journal:  Pediatr Nephrol       Date:  2007-09-18       Impact factor: 3.714

Review 4.  Pottransplantation anemia: management and rationale.

Authors:  Wolfgang C Winkelmayer; Anil Chandraker
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

Review 5.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

Review 6.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

7.  Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein.

Authors:  Nurcan Cengiz; Esra Baskin; Nurzen Sezgin; Pinar Agras; Mehmet Haberal
Journal:  Pediatr Nephrol       Date:  2008-10-29       Impact factor: 3.714

8.  Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy.

Authors:  Elísio Costa; Margarida Lima; João Moura Alves; Susana Rocha; Petronila Rocha-Pereira; Elisabeth Castro; Vasco Miranda; Sameiro Faria Maria do; Alfredo Loureiro; Alexandre Quintanilha; Luís Belo; Alice Santos-Silva
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

9.  Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.

Authors:  Mohammad I Saleh; Demet Nalbant; John A Widness; Peter Veng-Pedersen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

10.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.